Architect system
Device
Abbott Laboratories
Total Payments
$8.5M
Transactions
773
Doctors
265
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $224,844 | 55 | 10 |
| 2019 | $875,529 | 207 | 63 |
| 2018 | $3.6M | 362 | 160 |
| 2017 | $3.8M | 149 | 49 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.7M | 156 | 91.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $484,750 | 78 | 5.7% |
| Travel and Lodging | $82,662 | 113 | 1.0% |
| Grant | $50,000 | 1 | 0.6% |
| Royalty or License | $46,257 | 1 | 0.5% |
| Consulting Fee | $43,487 | 22 | 0.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $36,498 | 10 | 0.4% |
| Food and Beverage | $13,826 | 380 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $3,228 | 9 | 0.0% |
| Education | $56.25 | 3 | 0.0% |
Payments by Type
Research
$7.7M
156 transactions
General
$760,764
617 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Evaluation of Cardiovascular Biomarkers in the Randomized Evaluation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) TIMI-55 | Abbott Laboratories | $2.2M | 0 |
| Development of a Multi-Modality Classification Scheme for Traumatic Brain Injury | Abbott Laboratories | $726,431 | 0 |
| Evaluation of Cardiovascular Biomarkers in Patients with Type 2 Diabetes Mellitus and Established Atheroclerosis (EXAMINE) | Abbott Laboratories | $575,775 | 0 |
| Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) | Abbott Laboratories | $561,876 | 0 |
| Blood Biomarker Candidate Study for Mild Traumatic Brain Injury | Abbott Laboratories | $508,082 | 0 |
| Abbott Stress-Delta Biomarkers for ACS Risk Stratification | Abbott Laboratories | $446,000 | 0 |
| Cardiac Biomarkers for Prediction of Cardiac Events and Mortality After Non-Cardiac Surgery | Abbott Laboratories | $416,479 | 0 |
| De novo discovery of potential circulating TBI biomarkers in serum or plasma | Abbott Laboratories | $295,000 | 0 |
| Transforming Research and Clinical Knowledge in Traumatic Brain Injury TRACK TBI | Abbott Laboratories | $201,000 | 0 |
| Wyoming Clinical Specimen Collection Protocol for Evaluation of Abbott Laboratories in Vitro Diagnostic Assays | Abbott Laboratories | $198,385 | 0 |
| Exploring Viral Strain Diversity in the Democratic Republic of Congo | Abbott Laboratories | $171,583 | 0 |
| Evaluation of Existing TBI Biomarkers | Abbott Laboratories | $147,000 | 0 |
| Clinical Evaluation Protocol for ICQ Migration Studies | Abbott Laboratories | $142,038 | 0 |
| No Study Name Provided | Abbott Laboratories | $134,900 | 0 |
| Addition of High Sensitivity Troponin I assay to the Aggregate of 3 Pathway-related Biomarkers in Predicting High Near-term Risk of Myocardial Infarction and Death | Abbott Laboratories | $120,000 | 0 |
| Alinity I-STAT hsTNI Design Validation | Abbott Laboratories | $74,316 | 0 |
| ICQ System and Chemistry Immuno-Assays | Abbott Laboratories | $74,168 | 0 |
| Architect Cyclosporine Design Validation | Abbott Laboratories | $70,439 | 0 |
| The HYPNOS Trial | Abbott Laboratories | $67,596 | 0 |
| Troponin I Testing for the Diagnosis of Myocardial Injury after Noncardiac Surgery (MINS) in a Cancer Patient Population | Abbott Laboratories | $60,059 | 0 |
Top Doctors Receiving Payments for Architect system — Page 4
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Pediatrics | Westminster, MD | $57.58 | 2 |
| , DO | Internal Medicine | Cleveland, OH | $54.35 | 1 |
| , DDS | Dentist | San Marcos, TX | $49.10 | 3 |
| , D.O | Anatomic Pathology & Clinical Pathology | Fort Worth, TX | $47.85 | 2 |
| , M.D | Blood Banking & Transfusion Medicine | Milwaukee, WI | $45.00 | 3 |
| , MD | Emergency Medicine | Fort Washington, MD | $41.06 | 1 |
| , MD | Anatomic Pathology & Clinical Pathology | Oklahoma City, OK | $40.30 | 1 |
| , MD | Clinical Pathology/Laboratory Medicine | Oklahoma City, OK | $40.30 | 1 |
| , DO | Anatomic Pathology & Clinical Pathology | Morehead City, NC | $38.92 | 2 |
| , M.D | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Delray Beach, FL | $38.73 | 1 |
| , M.D | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Minneapolis, MN | $38.73 | 1 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Minneapolis, MN | $38.73 | 1 |
| , MD | Surgery | Washington, DC | $38.73 | 1 |
| , M.D | Obstetrics & Gynecology | Pottstown, PA | $38.01 | 1 |
| Molly Hubbard | — | Minneapolis, MN | $34.80 | 2 |
| , MD | Obstetrics | Boca Raton, FL | $33.97 | 2 |
| , MD | Clinical Pathology/Laboratory Medicine | Cleveland, OH | $32.77 | 1 |
| , MD | Hematology | Philadelphia, PA | $32.77 | 1 |
| , D.O | Specialist | Newtown, PA | $32.77 | 1 |
| , MD, PHD | Clinical Pathology/Laboratory Medicine | Sharon, PA | $32.02 | 2 |
| , M.D | Anatomic Pathology & Clinical Pathology | Oneonta, NY | $30.50 | 2 |
| , MD | Cytopathology | Fremont, CA | $30.31 | 2 |
| , MD | Anatomic Pathology & Clinical Pathology | Mobile, AL | $29.17 | 1 |
| , MD | Geriatric Medicine | Coatesville, PA | $29.12 | 1 |
| , M.D | Anatomic Pathology & Clinical Pathology | Temple, TX | $27.40 | 2 |
Ad
Manufacturing Companies
- Abbott Laboratories $8.5M
Product Information
- Type Device
- Total Payments $8.5M
- Total Doctors 265
- Transactions 773
About Architect system
Architect system is a device associated with $8.5M in payments to 265 healthcare providers, recorded across 773 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2017 to 2020. In 2020, $224,844 was paid across 55 transactions to 10 doctors.
The most common payment nature for Architect system is "Unspecified" ($7.7M, 91.0% of total).
Architect system is associated with 20 research studies, including "Evaluation of Cardiovascular Biomarkers in the Randomized Evaluation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) TIMI-55" ($2.2M).